# Christian Thirion

> Christian Thirion is a seed investor at SIRION BIOTECH backing Apps and Water. See 2 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: Angel Investor
- Fund: SIRION BIOTECH
- Total investments: 2
- Last investment: Aug 2025
- Lead investor: 50%
- Last updated: Aug 2026

Christian Thirion is a seed investor at SIRION BIOTECH focused on Apps and Water.

## Contacts

5 contacts available for Christian Thirion: work email, personal email, work phone, personal phone and socials. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-email/dr-christian-thirion?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Apps | 1 | 50% |
| Water | 1 | 50% |
| AgTech | 1 | 50% |
| Database | 1 | 50% |
| CleanTech | 1 | 50% |

8 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 50% |
| Series A | 1 | 50% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Denmark | 1 | 50% |
| United States | 1 | 50% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Amass Technologies | Amass Technologies researches and develops productivity through AI and machine learning tools. | $1.6M | Seed | Aug 22, 2025 |  |
| WaHa | WaHa has developed an innovative solid desiccant regeneration engine called the WaHa Vaporator®, which aims to revolutionize air conditioning technology. This patented system offers significant improvements in energy efficiency and greenhouse gas emissions for cooling, dehumidification, and atmospheric water generation applications.Key featuresof the WaHa Vaporator® include:- A novel approach to regenerating solid desiccants for air dehumidification - Independent control of dew point and dry bulb temperatures - Pure water generation, enabling direct evaporative cooling - Compatibility with ultra-low global warming potential refrigerants - Up to 90% reduction in energy consumption compared to conventional systems - Comparable size and weight to existing AC solutions and can be installed by current trades peopleThe WaHa Vaporator® is designed to be a versatile solution for air conditioning in any climate zones. It can also be used for cost-effective and energy efficient atmospheric water harvesting in any climate zone – including arid and cold climates. When compared to alternative technologies, it offers superior reliability and the lowest cost of ownership.WaHa was founded in 2018 to commercialize novel desiccant materials and technologies developed at UC Berkeley over two decades. The company has received seed funding from several sources, including UC Berkeley, Berkeley Catalyst Fund, Mitsui-Kinzoku, TAQNIA, and strategic angel investors. | $8M | Series A | Jul 10, 2025 |  |

2 of 2 investments shown.

## Co-investors
- [Anthropocene Institute](https://shizune.co/investors/profile/anthropocene-institute) — VC Fund, 1 deal together
- [Berkeley Catalyst Fund (BCF)](https://shizune.co/investors/profile/berkeley-catalyst-fund-bcf) — VC Fund, 1 deal together
- [Export and Investment Fund](https://shizune.co/investors/profile/export-and-investment-fund) — VC Fund, 1 deal together
- [Giant Ventures](https://shizune.co/investors/profile/giant-ventures-global) — VC Fund, 1 deal together
- [Kost Capital](https://shizune.co/investors/profile/kost-capital) — VC Fund, 1 deal together
- [Mitsui Mining & Smelting](https://shizune.co/investors/profile/mitsui-mining-smelting) — VC Fund, 1 deal together

## About SIRION BIOTECH

VC Fund · Martinsried, Germany

Viral Vector Technology as key enabler for innovative therapeutics. Viral vectors are a tool commonly used by molecular biologists to deliver genetic material into cells. This technique enables research of gene function and innovative therapeutics designed to correct defective genes and cancer. These technologies also assist in the discovery ofnew drug, food and cosmetic compounds. SIRION is a global leader in viral vector technology for gene modification of mammalian cells. Along with custom services, the company stands ready to outlicense its unique technologies. An initial target currently being pursued by one of SIRION's partners is a gene therapeutic for cervical cancer. The company started business in 2007 and since then has been changing the paradigm of viral vector supplies. Specifically, all commonly applied vector types are now available within a matter of weeks - adenovirus, adeno-associated virus (AAV) and lentivirus - and a full range of virus related services is at your fingertips spanning from particle production to virus driven cell modelling, all at highest titers and in quantities required for preclinical, clinical and animal testing.The company is easily accessible with presence in Munich, Tokyo, New Hampshire and Tel Aviv. Commercial arrangements range from fee-for-service over exclusive rights on single clones all the way to milestone & licensing arrangements. The business model proves successful: an annual 70% growth since 2007 and experienced in more than 500 projects for both the academic and industry sector.The company is privately held and has over the years raised funds from 8 investors both private and government. In order to support further growth and to benefit from technology development in this exciting industry, the company welcomes new investors. Please contact Management for further information about the company and its future plans.

5 contacts available at SIRION BIOTECH.

| Name | Title | Profile |
| --- | --- | --- |
| Carl Christel | Manager, Sales | — |
| Christian Thirion | CTO | https://shizune.co/investors/profile/dr-christian-thirion |
| Dieter Lingelbach | COO | — |
| Kathrin Schmitt | Director, Sales & Marketing | — |
| Michael Salomon | VP Development | — |

## Similar investors

### Similar industry
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Vaekstfonden](https://shizune.co/investors/profile/v%C3%A6kstfonden) — VC Fund
- [PSV](https://shizune.co/investors/profile/preseed-innovation) — VC Fund
- [Seed Capital](https://shizune.co/investors/profile/seed-capital) — VC Fund

## Featured in investor lists
- [Machine Learning Angel Investors in Denmark](https://shizune.co/investors/machine-learning-angel-investors-denmark)

## FAQ

### What does Christian Thirion invest in?

Christian Thirion invests primarily in Apps, Water and AgTech startups, most often at Seed and Series A stage. Most of the 2 investments tracked by Shizune back companies in Denmark. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Christian Thirion?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### When did Christian Thirion last invest?

The most recent investment recorded for Christian Thirion closed in Aug 2025. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co